Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 12/2/22 → 11/15/23 |
Funding
- Biohaven Pharmaceuticals Incorporated: $12,119.00
A Phase 2/3, Double-Blind, Randomized, Placebo- Controlled, Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Temporomandibular Disorders (TMD)
- Moreno Hay, Isabel (PI)